Sanara MedTech Inc., a medical technology company focused on surgical, chronic wound, and skin markets, reported a 28% increase in net revenue for the second quarter of 2025, reaching $25.8 million, compared to $20.2 million in the same quarter of 2024. The Sanara Surgical segment achieved a net income of $0.5 million and a Segment Adjusted EBITDA of $4.7 million in the second quarter, reflecting significant improvements year-over-year. For the first half of 2025, the segment incurred a net loss of $0.1 million but generated $7.4 million in Segment Adjusted EBITDA. In the THP segment, Sanara launched a pilot program with a wound care provider group in late June 2025, marking the beginning of patient encounters under this initiative. The segment, however, recorded a Segment Adjusted EBITDA of $(4.1) million for the first six months of 2025, compared to $(1.6) million for the same period in 2024. The company also announced a process to evaluate strategic alternatives for its Tissue Health Plus, LLC subsidiary. Cash flow from operating activities improved, with $0.7 million generated in the first half of 2025, compared to $3.0 million used in operating activities during the same period in 2024.